First Wave BioPharma, Inc. (FWBI)

2.7400 +0.0100 (+0.37%) At close: 04:00PM EDT

First Wave BioPharma, Inc.

777 Yamato Road
Suite 502
Boca Raton, FL 33431
United States
561 589 7020
https://www.firstwavebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. James R. Sapirstein M.B.A., R.Ph.	CEO & Chairman	906.2k	N/A	1961
Ms. Sarah Romano CPA	Chief Financial Officer	624.88k	N/A	1981
Dr. Jack A. Syage Ph.D.	President, COO & Director	N/A	N/A	1955
Ms. Amy Chandler-Skerkis	Vice President of Regulatory Affairs, QA & Compliance	N/A	N/A	1969
Mr. Martin Krusin M.B.A.	Senior Vice President of Corporate Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Corporate Governance

First Wave BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.